AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)

This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple-dose-escalation study evaluating the safety, tolerability, and immunogenicity of AV-1980R, an investigational vaccine targeting pathological tau, in participants with preclinical Alzheimer's disease. Up to 48 cognitively unimpaired adults aged 65 to 80 years with biomarker evidence of preclinical Alzheimer's disease will be enrolled into three ascending-dose cohorts.

NCT Number	NCT07158905
Lead Sponsor	Institute for Molecular Medicine Collaborators: National Institute on Aging (NIA)
Conditions	Alzheimer Disease, Preclinical Alzheimer's Disease
Enrollment	48 participants
Start Date	2026-06-23
Primary Completion	2029-06-15 (estimated)
Study Completion	2029-10-15 (estimated)
Updated on ClinicalTrials.gov	2026-08-04